Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation

Trial Profile

Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Adenovirus specific T cells Cell Medica (Primary)
  • Indications Adenovirus infections
  • Focus Adverse reactions
  • Acronyms ASPIRE
  • Sponsors Cell Medica
  • Most Recent Events

    • 01 Aug 2018 According to a Cell Medica media release, results of this study have been published in Cytotherapy Journal (2018).
    • 01 Aug 2018 Results presented in a Cell Medica media release.
    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top